Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)
Clinical trial NCT06917911 · RECRUITING
Trial details
- NCT number
- NCT06917911
- Sponsor
- National Cancer Institute (NCI)
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2027-02-02
- Primary completion
- 2027-11-25
- Enrollment
- 162
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.